Oncologica is the first laboratory in Europe to offer the Oncofocus assay for personalised oncology.
Our targeted next generation sequencing (NGS) assay enables simultaneous detection of thousands of genetic variants across the major driver genes relevant to solid tumours. Targeted actionable hotspots include SNVs, indels, CNVs and gene fusions. Notably these driver cancer genes have been selected because they are the most clinically relevant and have been approved for reimbursement in the US. Analysis of the output from the Oncofocus Test is performed using Oncofocus Reporter, an analytical system used to identify and prioritize potential treatment strategies. This informatics pipeline represents a curated set of published evidence from clinical trials that supports the matching of driver genetic variants with clinical therapeutic options. Oncologica carries out DNA sequencing of patient tumour samples using semiconductor chip technology directly translating chemically encoded information (A,C,G,T) into digital information. Semiconductor sequencing has major advantage over other sequencing technologies because it can be used to sequence low DNA input FFPE biopsy samples with high throughput and at reduced cost. Comprehensive analysis of major cancer driver genes in one single workflow dramatically reduces the cost of molecular profiling and accelerates reporting times. The Oncofocus Test generates a comprehensive picture of actionable mutations providing the clinician with a detailed molecular blue print for optimal therapy choices and improved patient outcomes and prevents the unwarrented prescribing of expensive targeted therapies to patients unlikely to benefit from such treatments. Detected variants are linked to clinical therapeutic options including:
- FDA approved therapies
- guideline referenced therapies
- NCCN, EMA and ESMO guidelines in the patients’ cancer type
- variants referenced in NCCN, EMA and ESMO guidelines in another cancer type
- therapies entered into worldwide phase I, II, III and IV clinical trials (variants referenced as inclusion criteria in clinical trials)
Targeted NGS for all Solid Tumour Types LUNG CANCER

Targeted NGS for all Solid Tumour Types MELANOMA

Targeted NGS for all Solid Tumour Types PROSTATE TUMOUR

LONGITUDINAL DYNAMIC MONITORING

ONCOFOCUS SERVICE FLOW
